Get started
Author

Masahiko Kondo

Observed names: M Kondo, M. Kondo, MASAHIKO KONDO
ORCID: 0000-0003-0435-4909
Observed ORCID: 0000-0003-0435-4909
OpenAlex ID: A5102743719
The Real-World Data in Japanese Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib from a Nationwide Multicenter Study
2021 · Kaoru Tsuchiya, Masayuki Kurosaki, et al. · Cancers · 54
PDF
Usefulness of neutrophil‐to‐lymphocyte ratio in predicting progression and survival outcomes after atezolizumab–bevacizumab treatment for hepatocellular carcinoma
2022 · Hironori Ochi, Masayuki Kurosaki, et al. · Hepatology Research · 51
PDF
Change in Fibrosis 4 Index as Predictor of High Risk of Incident Hepatocellular Carcinoma After Eradication of Hepatitis C Virus
2020 · Nobuharu Tamaki, Masayuki Kurosaki, et al. · Clinical Infectious Diseases · 45
PDF
Real‐world efficacy and safety of sofosbuvir + ribavirin for hepatitis C genotype 2: A nationwide multicenter study by the Japanese Red Cross Liver Study Group
2018 · Takehiro Akahane, Masayuki Kurosaki, et al. · Hepatology Research · 33
Real‐world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1‐ and 2‐infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group
2021 · Toshifumi Tada, Masayuki Kurosaki, et al. · Journal of Medical Virology · 30
A case of ectopic hepatocellular carcinoma in the jejunum
2006 · Masato Shigemori, Masahiko Kondo, et al. · Journal of Gastroenterology · 28
Tumor invasion to the arteries feeding the gallbladder as a novel risk factor for cholecystitis after metallic stent placement in distal malignant biliary obstruction
2017 · Yuko Sogabe, Yuzo Kodama, et al. · Digestive Endoscopy · 23
Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study Group
2023 · Shintaro Takaki, Masayuki Kurosaki, et al. · Investigational New Drugs · 21
Detectable HBV DNA during nucleos(t)ide analogues stratifies predictive hepatocellular carcinoma risk score
2020 · Shun Kaneko, Masayuki Kurosaki, et al. · Scientific Reports · 20
PDF
Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis
2023 · Daniel Q. Huang, Nobuharu Tamaki, et al. · Hepatology · 19
Hepatocellular Carcinoma Risk Assessment for Patients With Advanced Fibrosis After Eradication of Hepatitis C Virus
2021 · Nobuharu Tamaki, Masayuki Kurosaki, et al. · Hepatology Communications · 19
PDF
Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab
2022 · Nobuharu Tamaki, Toshifumi Tada, et al. · Investigational New Drugs · 18
Real-World Data on Ramucirumab Therapy including Patients Who Experienced Two or More Systemic Treatments: A Multicenter Study
2022 · Yutaka Yasui, Masayuki Kurosaki, et al. · Cancers · 13
PDF
Viral eradication reduces all‐cause mortality in patients with chronic hepatitis C virus infection who had received direct‐acting antiviral therapy
2024 · Toshifumi Tada, Masayuki Kurosaki, et al. · Liver International · 12
PDF
A validation study of after direct‐acting antivirals recommendation for surveillance score for the development of hepatocellular carcinoma in patients with hepatitis C virus infection who had received direct‐acting antiviral therapy and achieved sustained virological response
2021 · Toshifumi Tada, Masayuki Kurosaki, et al. · JGH Open · 12
PDF
Efficacy of daclatasvir plus asunaprevir in patients with hepatitis C virus infection undergoing and not undergoing hemodialysis
2018 · Hideki Fujii, Hiroyuki Kimura, et al. · Hepatology Research · 12
Risk factors for hepatocellular carcinoma at baseline and 1 year after initiation of nucleos(t)ide analog therapy for chronic hepatitis B
2022 · Shun Kaneko, Masayuki Kurosaki, et al. · Journal of Medical Virology · 9
Pemafibrate improves liver biochemistry and GLOBE scores in patients with primary biliary cholangitis: Nationwide, multicenter study by the Japanese Red Cross Liver Study Group
2025 · Keiji Tsuji, Nobuharu Tamaki, et al. · Hepatology Research · 8
Successful Endoscopic Dilation Treatment of Small Intestinal Stricture Occurring during Chemotherapy for Malignant Lymphoma
2010 · Yusuke Honzawa, Masahiko Kondo, et al. · Case Reports in Gastroenterology · 6
PDF
Effect of Direct‐Acting Antivirals on Prognosis in Older Patients With Hepatitis C Virus‐Related Hepatocellular Carcinoma After Curative Therapy: A Retrospective Study by the Red Cross Liver Study Group in Japan
2026 · Hironori Ochi, Masayuki Kurosaki, et al. · Hepatology Research · 4
Effect of Pemafibrate on Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Nationwide Multicenter Study
2025 · Yasuyuki Komiyama, Nobuharu Tamaki, et al. · JGH Open · 4
PDF
Effect of treatment periods on efficacy of glecaprevir and pibrentasvir in chronic hepatitis C: A nationwide, prospective, multicenter study
2024 · Atsuhiro Morita, Nobuharu Tamaki, et al. · JGH Open · 4
Necessity for surveillance for hepatocellualr carcinoma in older patients with chronic hepatitis C who achieved sustained virological response
2023 · Shun Ishido, Nobuharu Tamaki, et al. · JGH Open · 4
PDF
Efficacy of hepatitis C virus eradication after curative treatment for hepatocellular carcinoma in patients with advanced hepatocellular carcinoma and decreased hepatic functional reserve: A nationwide, multicentre study by the Japanese Red Cross Liver Study Group
2022 · Toshie Mashiba, Kouji Joko, et al. · Journal of Viral Hepatitis · 4
The efficacy and safety of lenvatinib in patients who did not meet the inclusion criteria of the phase 3 trial (REFLECT trial) in real-world practice in Japan: A nationwide multicenter study in Japan.
2019 · Kaoru Tsuchiya, Masayuki Kurosaki, et al. · Journal of Clinical Oncology · 4
Works count: 35
Citation count: 471
H-index: 13
I10-index: 16
Year
Topic
Type